argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of g...
Q2 2026
Jul 23, 2026
Q1 2026
May 7, 2026
FY 2025
Mar 19, 2026
Q4 2025
Q3 2025
Oct 30, 2025